Retatrutide has emerged as a new treatment in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in investigations. By activating these https://blancheacce350360.gynoblog.com/35275082/tirzepatide-a-promising-new-treatment-for-obesity